Nasal Foralumab for the Treatment of Progression Independent of Relapses in Patients With Nonactive Secondary Progressive Multiple Sclerosis

Neurology® Neuroimmunology & Neuroinflammation · 2026 · PMC12815464

Europe PMC

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Olink 48-plex cytokine analysis in the CSF of foralumab-treated patients at baseline (T1) and 6 months (T2), showed a trend in reduction of CXCL12 (eFigure 8B). scRNAseq scRNAseq of peripheral blood mononuclear cells (PBMC) samples at baseline and 3 and 6 months in 4 patients shows changes in overall gene expression at the 3-month time point and sustained at 6 months ( Figure 3 ).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.